Pediatrics

Amy Houtrow, MD, PhD, MPH, considers the impact of poverty on childhood disability and talks about opportunities to breach barriers to health care access.

Renowned pediatric rehabilitation physician Amy Houtrow, MD, PhD, MPH, highlights the scope of the specialty and its core objectives.

Your daily dose of the clinical news you may have missed.

An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.

Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.

Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.

Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).

Tina Tan, MD, FAAP, FIDSA, FPIDS, presents the background, objectives, and methods of a recent study on the efficacy and safety of nirsevimab for Respiratory Syncytial Virus (RSV) in late-preterm and term infants.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, introduce the objectives of their discussion and background information on Respiratory Syncytial Virus (RSV) and nirsevimab.

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

A daily dose of clinical news on Patient Care you may have missed.

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.

A daily dose of clinical news on Patient Care you may have missed.

Approximately 80% of infants hospitalized with an RSV-related illness during the 2022 seasonal peak did not have underlying medical conditions, according to new study.

The AAP released 12 tips to prepare children to return to school this year, including several that focus on mental health.

A daily dose of clinical news you may have missed.

Nirsevimab won unanimous support from the FDA AMDAC on the vaccine's positive benefit/risk profile to prevent RSV in newborns and infants in their first RSV season.

Your daily dose of clinical news you may have missed.

FDA approval of the monoclonal antibody against RSV follows the unanimous vote from the agency's Antimicrobial Drugs Advisory Committee.